Weil Company Inc. raised its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 4.2% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 15,687 shares of the company’s stock after purchasing an additional 629 shares during the quarter. Johnson & Johnson accounts for approximately 1.5% of Weil Company Inc.’s portfolio, making the stock its 16th largest position. Weil Company Inc.’s holdings in Johnson & Johnson were worth $2,578,000 at the end of the most recent quarter.
Other hedge funds have also made changes to their positions in the company. Fifth Third Bancorp increased its stake in Johnson & Johnson by 2.5% during the 1st quarter. Fifth Third Bancorp now owns 1,430,742 shares of the company’s stock valued at $235,142,000 after purchasing an additional 35,299 shares in the last quarter. Essex Investment Management Co. LLC boosted its holdings in Johnson & Johnson by 95.5% during the 4th quarter. Essex Investment Management Co. LLC now owns 481 shares of the company’s stock worth $76,000 after acquiring an additional 235 shares during the last quarter. British Airways Pensions Investment Management Ltd boosted its holdings in Johnson & Johnson by 15.9% during the 1st quarter. British Airways Pensions Investment Management Ltd now owns 205,847 shares of the company’s stock worth $33,831,000 after acquiring an additional 28,175 shares during the last quarter. Bank Julius Baer & Co. Ltd Zurich boosted its holdings in Johnson & Johnson by 58.0% during the 1st quarter. Bank Julius Baer & Co. Ltd Zurich now owns 991,588 shares of the company’s stock worth $162,967,000 after acquiring an additional 364,145 shares during the last quarter. Finally, WASHINGTON TRUST Co boosted its holdings in Johnson & Johnson by 0.4% during the 1st quarter. WASHINGTON TRUST Co now owns 182,744 shares of the company’s stock worth $30,033,000 after acquiring an additional 810 shares during the last quarter. Institutional investors and hedge funds own 66.74% of the company’s stock.
A number of equities analysts have issued reports on the stock. Credit Suisse Group set a $193.00 price objective on shares of Johnson & Johnson and gave the stock a “buy” rating in a report on Monday. Morgan Stanley assumed coverage on shares of Johnson & Johnson in a report on Friday, May 28th. They set an “overweight” rating and a $187.00 price objective on the stock. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and ten have assigned a buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average price target of $182.45.
Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings data on Monday, April 19th. The company reported $2.59 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $2.34 by $0.25. The business had revenue of $22.30 billion for the quarter, compared to the consensus estimate of $22 billion. Johnson & Johnson had a net margin of 17.95% and a return on equity of 34.62%. The company’s revenue was up 7.8% compared to the same quarter last year. During the same period in the prior year, the firm earned $2.30 earnings per share. On average, equities research analysts forecast that Johnson & Johnson will post 9.51 earnings per share for the current fiscal year.
The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, June 8th. Shareholders of record on Tuesday, May 25th were issued a dividend of $1.06 per share. The ex-dividend date was Monday, May 24th. This is an increase from Johnson & Johnson’s previous quarterly dividend of $1.01. This represents a $4.24 annualized dividend and a yield of 2.53%. Johnson & Johnson’s dividend payout ratio is 52.80%.
Johnson & Johnson Company Profile
Johnson & Johnson researches and develops, manufactures, and sells a range of products in the health care field worldwide. It operates through three segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR.
See Also: What’s a Black Swan?
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.